Skip to main content
Toggle navigation
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Print
Presentation of Best Lymphoma Abstract: Subcutaneous Epcoritamab Combined With Rituximab + Lenalidomide for the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update
Saturday, October 22, 2022
10:40 AM – 10:50 AM
